GlaxoSmithKline is fined record $3bn in US
17:15 EDT 3 Jul 2012 | British Medical Journal
GlaxoSmithKline has agreed to plead guilty and pay $3bn (£2bn; €2.4bn) in penalties for unlawful promotion of prescription drugs, failure to report safety data, and false price reporting.It also...
Original Article: GlaxoSmithKline is fined record $3bn in US
More From BioPortfolio on "GlaxoSmithKline is fined record $3bn in US"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
